News | October 27, 2022
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
